Home > Browse Research > Life Sciences > Pharmaceuticals > Drug Discovery

Drug Discovery: market research reports

Drug Discovery market research reports and industry analysis

Soft Tissue Sarcoma – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma ... \| read more...	$2,000.00
Infantile Hemangiomas – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Infantile Hemangiomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Infantile Hemangiomas. Infantile Hemangiomas - Pipeline Review, Half Year ... \| read more...	$2,000.00
Influenza A And B Infections – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... provides information on the therapeutic development for Influenza A And B Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for ... \| read more...	$2,000.00
Metastatic Adenocarcinoma of The Pancreas – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... provides information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for ... \| read more...	$2,000.00
Relapsing Multiple Sclerosis (RMS) – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis ... \| read more...	$2,000.00
Enterococcus Infections – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Enterococcus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Infections. Enterococcus Infections - Pipeline Review, Half Year ... \| read more...	$2,000.00
Cerebral Palsy – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Cerebral Palsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cerebral Palsy. Cerebral Palsy - Pipeline Review, Half Year ... \| read more...	$2,000.00
Hyperglycemia – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperglycemia. Hyperglycemia - Pipeline Review, Half Year is built using data and ... \| read more...	$2,000.00
Keloids – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Keloids. Keloids - Pipeline Review, Half Year is built using data and ... \| read more...	$2,000.00
Gastric Motility Disorder – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Gastric Motility Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Motility Disorder. Gastric Motility Disorder ... \| read more...	$2,000.00
Male Sexual Dysfunction – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Male Sexual Dysfunction ... \| read more...	$2,000.00
Arrhythmias – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arrhythmias. Arrhythmias - Pipeline Review, Half Year is built using data and ... \| read more...	$2,000.00
Inflammatory Pain Global Clinical Trials Review, H1, 2013 4/30/2013 \| published by: GlobalData ... information and data relating to the clinical trials on Inflammatory Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ... \| read more...	$2,500.00
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also ... \| read more...	$2,000.00
Acute Spinal Cord Injury – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord ... \| read more...	$2,000.00
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 81 companies plus partners developing 67 NOD-like receptor signaling pathway targeting drugs in 186 developmental ... \| read more...	$3,746.25
Notch Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... are today 159 companies plus partners developing 175 Notch pathway targeting drugs in 583 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last ... \| read more...	$5,621.25
Ovarian Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... an important secondary indication for existing and pipeline drugs. There are today 220 companies plus partners developing 306 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number ... \| read more...	$5,621.25
Peptides in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... number of ceased drugs over the last years amount to another 122 drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ... \| read more...	$5,621.25
PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... translation, proliferation, growth, and survival. There are today 439 companies plus partners developing 763 PI3K-Akt signaling pathway targeting drugs in 2339 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated ... \| read more...	$7,496.25
Prostate Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy ... \| read more...	$5,621.25
Radiation Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 679 developmental projects in cancer. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 132 drugs. Radiation Therapy In Oncology Drug Pipeline Update ... \| read more...	$5,621.25
Renal Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets. There are today ... \| read more...	$5,621.25
RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... a result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). There are today 53 companies plus partners developing 33 RIG-I-like receptor signaling pathway targeting drugs in ... \| read more...	$1,871.25

< prev 1 2 3 4 5 6 7 8 9 10 next >